BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30849450)

  • 1. B cells in chronic graft-versus-host disease.
    McManigle W; Youssef A; Sarantopoulos S
    Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.
    Jia W; Poe JC; Su H; Anand S; Matsushima GK; Rathmell JC; Maillard I; Radojcic V; Imai K; Reyes NJ; Cardona DM; Li Z; Suthers AN; Curry-Chisolm IM; DiCioccio RA; Saban DR; Chen BJ; Chao NJ; Sarantopoulos S
    Blood; 2021 May; 137(18):2544-2557. PubMed ID: 33534893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased BCR responsiveness in B cells from patients with chronic GVHD.
    Allen JL; Tata PV; Fore MS; Wooten J; Rudra S; Deal AM; Sharf A; Hoffert T; Roehrs PA; Shea TC; Serody JS; Richards KL; Jagasia M; Lee SJ; Rizzieri D; Horwitz ME; Chao NJ; Sarantopoulos S
    Blood; 2014 Mar; 123(13):2108-15. PubMed ID: 24532806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
    Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J
    Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
    Sarantopoulos S; Stevenson KE; Kim HT; Cutler CS; Bhuiya NS; Schowalter M; Ho VT; Alyea EP; Koreth J; Blazar BR; Soiffer RJ; Antin JH; Ritz J
    Blood; 2009 Apr; 113(16):3865-74. PubMed ID: 19168788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
    Allen JL; Fore MS; Wooten J; Roehrs PA; Bhuiya NS; Hoffert T; Sharf A; Deal AM; Armistead P; Coghill J; Gabriel DA; Irons R; Essenmacher A; Shea TC; Richards K; Cutler C; Ritz J; Serody J; Baldwin AS; Sarantopoulos S
    Blood; 2012 Sep; 120(12):2529-36. PubMed ID: 22896003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.
    Poe JC; Jia W; Su H; Anand S; Rose JJ; Tata PV; Suthers AN; Jones CD; Kuan PF; Vincent BG; Serody JS; Horwitz ME; Ho VT; Pavletic SZ; Hakim FT; Owzar K; Zhang D; Blazar BR; Siebel CW; Chao NJ; Maillard I; Sarantopoulos S
    Blood; 2017 Nov; 130(19):2131-2145. PubMed ID: 28851699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
    Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
    Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
    Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
    PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
    Front Immunol; 2020; 11():1505. PubMed ID: 32849514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cells in chronic graft-versus-host disease.
    Sarantopoulos S; Blazar BR; Cutler C; Ritz J
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
    Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
    Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
    Kharfan-Dabaja MA; Bazarbachi A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
    Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
    Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
    J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease.
    Yehudai-Ofir D; Henig I; Zuckerman T
    Autoimmun Rev; 2020 Apr; 19(4):102493. PubMed ID: 32062034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.
    Whillock AL; Ybarra TK; Bishop GA
    J Biol Chem; 2021; 296():100465. PubMed ID: 33639170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
    Nakasone H; Sahaf B; Miklos DB
    Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.